This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.
Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market
by Zacks Equity Research
Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.
Syneos Health (SYNH) Expands Catalyst Site Program to China
by Zacks Equity Research
Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.
Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth
by Zacks Equity Research
In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
by Zacks Equity Research
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch
by Zacks Equity Research
Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.
Boston Scientific (BSX) Expands Globally Amid FX Concerns
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
CVS Health's (CVS) Cordavis to Focus on Biosimilar Products
by Zacks Equity Research
CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.
NanoString (NSTG) Advances in Xenotransplantation With New Study
by Zacks Equity Research
NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
by Zacks Equity Research
Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.
Align (ALGN) Rides on Growing Invisalign Sales, New Alliances
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
by Zacks Equity Research
Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.
Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs
by Zacks Equity Research
Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.
Illumina (ILMN) Expands Presence in India With New Facility
by Zacks Equity Research
Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 18.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD
by Zacks Equity Research
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.
Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 11.77%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 37.50% and 4.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 129.17% and 11.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 2.76%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?